<DOC>
	<DOC>NCT00943449</DOC>
	<brief_summary>The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to Sorafenib monotherapy.</brief_summary>
	<brief_title>4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Main Advanced stage hepatocellular carcinoma Patients exhibiting progressive disease under Sorafenib treatment ChildPugh class A and B. Only patients with ChildPugh index class B of not more than 7 will be included ECOG performance status 0, 1 or 2 Precedent firstline treatment with Sorafenib minimum continuous dosing of 400 mg per day for at least 8 weeks Main Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1) any cancer curatively treated &gt; 3 years prior to entry is permitted Renal failure requiring hemo or peritoneal dialysis Known central nervous system (CNS) tumors including symptomatic brain metastasis ChildPugh index class B in combination with more than slight ascites or hepatic encephalopathy &gt; Grade I Pregnant or breastfeeding women Sorafenib intolerance Major surgery within the last 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>HDAC</keyword>
	<keyword>4SC-201</keyword>
	<keyword>Phase II</keyword>
	<keyword>Resminostat</keyword>
</DOC>